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In North America, Chagas disease
(American trypanosomiasis caused by Try-
panosoma cruzi) was first reported in Mexico
in 1940 [1] and in the United States in
Texas in 1955 [2]. However, based on
ancient mummified remains discovered in
the Rio Grande Valley, human T. cruzi
infection has been present in North Amer-
ica since prehistoric times [3].
T. cruzi is a protozoan hemoflagellate
that is most commonly transmitted to
humans by blood-feeding triatomine bugs
followed by autoinoculation [2]. Chagas
disease can also be transmitted to man by
non-vectorial mechanisms, namely moth-
er-to-child-transmission [4], blood trans-
fusion, and orally through food-borne
transmission. When untreated in the acute
stage, the disease becomes chronic and up
to 30% or more of infected individuals will
progress to Chagasic cardiomyopathy or
megavisceral disease associated with de-
bilitating morbidity or death. Today,
Chagas disease is a leading cause of heart
disease among people living in extreme
poverty in the Western Hemisphere,
especially in Latin America, where it is a
major parasitic killer [2].
The established link between poverty
and Chagas disease transmission derives
largely from poor-quality housing that
facilitates triatomine bug invasion, togeth-
er with lack of access to adequate health
care and antenatal care. Additional factors
related to poverty also include lack of
health education and environmental man-
agement leading to vector invasion and
colonization [5]. Despite enormous strides
made in Chagas vector control, through
housing improvements and aggressive
insecticidal spraying, and case reduction
or even elimination in parts of Latin
America [6], important areas of high
endemicity persist, including in North
America. Confirmatory data are scarce,
but, according to some preliminary esti-
mates, Mexico ranks number three, and
the United States number seven, in terms
of the number of infected individuals with
Chagas disease in the Western Hemi-
sphere, where 99% of the cases occur
[2]. In Mexico, an earlier national sero-
prevalence survey reported a rate of 1.6%
[7]. However, other reports have provided
alternative estimates ranging between
1.0% and 5.9% (i.e., between one to six
million cases nationwide) [1,2]. In the
U.S., approximately 300,000 cases are
believed to be present [2], although one
alternative estimate reports more than
250,000 cases in Texas alone [8], with
up to one million or more cases nation-
wide (Figure 1) [9]. Thus, together with
several thousand cases in Canada, there
are between 1.5 million (lower estimate)
and 7 million (highest estimate) cases of
Chagas disease among the 500 million
people living in North America. Clearly,
there is a need for active surveillance data
in order to better refine these prevalence
data.
Equally troubling are suggestions that
40,000 pregnant North American women
may be infected with T. cruzi at any given
time, resulting in 2,000 congenital cases
through mother-to-child transmission [4].
According to the Pan American Health
Organization, congenital transmission
may currently account for more than
one-quarter of the world’s new Chagas
disease cases [2,6].
While North America appears to have a
high disease burden resulting from T. cruzi
infection, in actuality we know remarkably
little about the epidemiology of Chagas
disease in this region. No systematic effort
has been undertaken to ascertain the true
national prevalence of Chagas disease in
Mexico, even though some isolated com-
munities are now withering because be-
tween 30% and 50% of their populations
are infected with T. cruzi [10–12]. In
addition, Chagas disease is the most
common cause of dilated cardiomyopathy
in some areas of southern Mexico [13],
and a significant percentage of mothers
are infected with T. cruzi [14]. According
to one estimate the overall economic losses
from Chagas disease in Mexico may
exceed $3 billion annually [8].
Similarly, in the U.S., no effort to
conduct widespread surveillance testing
has ever been organized in the states
considered at highest risk of T. cruzi
infection, and, while most of the human
cases are presumed to have been intro-
duced through immigration [2], it is
known that triatomine vectors infected
with T. cruzi are present throughout
southern Texas and elsewhere in the
U.S. [15]. Ironically, we may know more
about canine Chagas disease transmission,
which is widespread in Texas [16]. While
seven autochthonous vector-transmitted
human cases in the U.S. had been
reported previously [2], the screening of
blood donors initiated in 2007 has led to
the identification of 16 additional cases
[17], but many more may exist, especially
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given the pervasive ignorance among
physicians and other health-care providers
on how to recognize and diagnose Chagas
disease and how it is transmitted [2,18].
To underscore the lack of awareness
among clinicians, the first congenital case
of Chagas disease in the U.S. was reported
in 2012, more than 50 years after the first
documented case [19].
Alongside the gaps in surveillance is the
dearth of health-care facilities offering
diagnosis and treatment of Chagas disease
in the U.S. Currently, we believe that Los
Angeles and Houston have two of the
largest clinics for diagnosing and treating
the disease. Until recently, treatment of
Chagas with benznidazole was thought to
be safe and effective only for newborns
and infants. The experience of Doctors
Without Borders/Me´decins Sans Fron-
tie`res in Latin American countries has
shown that treatment with benznidazole is
indeed possible—and safe—for children
and adults alike, provided regular medical
checks are performed [20]. Such activities
complement similar, concurrent efforts to
evaluate Chagas disease therapies [21,22].
It is thus imperative to scale up access to
benznidazole treatment while simulta-
neously investing in research for new
diagnostics, drugs, and vaccines.
Similar to other endemic countries in
Latin America where scaling up appropri-
ate diagnosis and treatment remains a
major challenge for Chagas disease pa-
tients, the need to address and reduce the
burden of Chagas disease in North
America is substantial: In Mexico, imple-
menting a national program of surveil-
lance and disease burden assessment is
urgently needed, in addition to sustaining
vector control efforts, providing accessible
programs of case management, and im-
plementing treatment in the most affected
and impoverished areas of Mexico (i.e.,
Chiapas, Guerrero, Jalisco, Oaxaca, Ver-
acruz, and the Yucatan peninsula) [1].
Without such actions, and in the absence
of vector control, the Chagas disease
burden could double in 25 years [8].
Moreover, in our experience, the waiting
list for benznidazole (one of two drugs for
the antiparasitic chemotherapy of Chagas
disease) can be excessive – therefore a
program to accelerate access to this
essential medicine needs to be implement-
ed. All pregnant women in Chagas
disease-endemic regions of Mexico should
be tested for T. cruzi infection and offered
treatment after delivery and/or after
completing breastfeeding. All infants with
congenital Chagas disease need to be
treated; a new pediatric dosage form of
benznidazole developed by the Drugs for
Neglected Diseases initiative (DNDi) is
now available. In addition, children born
Figure 1. Estimated number of Chagas disease cases in North America.
doi:10.1371/journal.pntd.0002300.g001
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during previous pregnancies should also
be screened and treated once a mother is
identified as infected with T. cruzi, as
suggested for northern Argentina [23],
while overall, new and improved algo-
rithms are needed to address more wide-
spread testing such as testing on women of
child-bearing age that migrate from en-
demic to non-endemic areas.
In the U.S., increased support for
federal, state, and local public health
agencies is needed to implement a similar
program of surveillance, disease burden
assessment, and treatment programs in
Texas and other southern states, and for
some urban communities with large pop-
ulations of immigrants from Chagas dis-
ease-endemic areas. The barriers [24] and
cost-effectiveness of immigrant screening,
including screening of pregnant women
[25,26], have been noted. Equally urgent
is the need to assess the risks of transmis-
sion in disease-endemic areas, looking at
vectors and reservoir host distributions [1],
and to tease out which cases might be
transmitted from within the borders of the
U.S. There is an urgent need for more,
and better, data on human infection in
areas where infected vectors and reservoirs
have been identified. Regulatory issues
surrounding the use of benznidazole in
the U.S. must be addressed to provide
expanded treatment options. The U.S. is
also faced with a health care workforce
that now obtains very little, if any, formal
training in medical parasitology, so that, at
best, physicians are only modestly aware of
how to recognize the signs and symptoms
of Chagas disease, let alone identify at-risk
individuals, obtain clinical testing, and
begin appropriate care for patients
[2,18]. Such lack of awareness is especially
acute among obstetricians caring for T.
cruzi-infected expectant mothers [2,4].
Finally, health research in Mexico needs
to be prioritized based on disease burden
estimates [27], while research capacity for
Chagas disease across North America
needs to be expanded to develop or
improve current treatments. We desper-
ately require improved drugs, as the two
currently available to treat Chagas disease
are of limited efficacy in some clinical
situations, have undesirable adverse
events, and are contraindicated in preg-
nancy so that we have nothing to offer
pregnant women at risk of passing their T.
cruzi infection onto their unborn fetuses
[28]. Neither benznidazole, nor nifurti-
mox, is approved by the U.S. Food and
Drug Administration. DNDi is currently
developing a new azole drug candidate
that may have a better safety profile, with
clinical testing in progress. Concurrently a
therapeutic Chagas vaccine is under
development by a consortium of Mexican
(including the Carlos Slim Health Insti-
tute) and Texan scientific institutions [29].
We also need more sensitive diagnostics
that can be used at point-of-care, and
biomarkers to assess therapeutic response
and progression of cardiac disease in the
setting of T. cruzi infection [2]. Without
new tools, disease control will not be
possible for Chagas disease, and the U.S.
and other governments have a major role
to play in ensuring innovation—from
basic research to late-stage product devel-
opment—is funded and carried out.
The poorest people living in the Mexico
and the U.S. are silently suffering under a
heavy burden of Chagas disease, with
pregnant women disproportionately affect-
ed. We can save many lives with greater
access to the treatments available today,
while knowing the fate of tomorrow’s
patients rests on increasing investments
in research to develop new technologies to
treat and diagnose Chagas disease, as well
as improving scientific cooperation be-
tween the U.S., Canada, Mexico, and
other key countries. Ultimately, scientific
breakthroughs for new technologies to
fight Chagas disease will be the corner-
stone of efforts to control this ancient
scourge in North America and beyond.
References
1. Cruz-Reyes A, Pickering-Lopez JM (2006) Cha-
gas disease in Mexico: an analysis of geographical
distribution during the past 76 years – a review.
Mem Inst Oswaldo Cruz, Rio de Janeiro; 101:
345–354.
2. Bern C, Kjos S, Yabsley MJ, Montgomery SP
(2011) Trypanosoma cruzi and Chagas’ disease in
the United States. Clin Microbiol Rev 2011; 24:
655–81.
3. Araujo A, Jansen AM, Reinhard K, Ferreira LF
(2009) Paleoparasitology of Chagas disease – a
review. Mem Inst Oswaldo Cruz, Rio de Janeiro;
104 (Suppl I): 9–16.
4. Buekens P, Almendares O, Carlier Y, Dumonteil
E, Eberhard M, et al. (2008) Mother-to-child
transmission of Chagas’ disease in North Amer-
ica: why don’t we do more? Matern Child
Health J; 12: 283–6.
5. Gurevitz JM, Ceballos LA, Gaspe MS, Alvarado-
Otegul JA, Enreiquez GF, et al. (2011) Factors
affecting infestation by Triatoma infestans in a
rural area of the humid Chaco in Argentina: a
multi-model inference approach. PLOS Negl
Trop Dis; 5: e1349. doi: 10.1371/journal.
pntd.0001349.
6. Organizacion Panamericana de la Salud (2006)
Estimacion cuantitativa de la enfermedad de
Chagas en las Americas OPS/HDM/CD/425-
06. Organizacion Panamerica de la Salud,
Washington, DC.
7. Guzman-Bracho C (2001) Epidemiology of Cha-
gas disease in Mexico: an update. Trends
Parasitol 17: 372–6.
8. Hanford EJ, Zhan FB, Lu Y, Giordano A (2007)
Chagas disease in Texas: recognizing the signif-
icance and implications of evidence in the
literature. Soc Sci Med; 65: 60–79.
9. Hotez PJ (2008) Neglected infections of poverty
in the United States of America.PLOS Negl
Trop Dis; 2: e256. doi: 10.1371/journal.
pntd.0000256.
10. Attaran A (2006) Chagas’ disease in Mexico.
Lancet; 368: 1768.
11. Capps L, Begona A (2004) Chagas cardiomyop-
athy and serologic testing in a small rural hospital
in Chiapas, Mexico. Rev Panam Salud Publica;
15: 337–40.
12. Ramos-Ligonio A, Lopez-Monteon A, Guzman-
Gomez D, Rosales-Encina JL, Limon-Flores Y,
Dumonteil E (2010) Identification of a hyperen-
demic area for Trypanosoma cruzi infection in
central Veracruz, Mexico. Am J Trop Med Hyg;
83: 164–70.
13. Sierra-Johnson J, Olivera-Mar A, Monteon-
Padilla VM, Reyes PA, Vallejo M (2005)
Epidemiological and clinical outlook of chronic
Chagas’ heart disease in Mexico. Rev Saude
Publica; 39: 754–60.
14. Olivera Mar A, Guillen Ortega F, Cruz Vidal S,
Hernandez-Becerril N, Perez Galdamez E, et al
(2006) Serological and parasitological screening of
Trypanosoma cruzi infection in mothers and
newborns living in two Chagasic areas of Mexico.
Arch Med Res; 37: 774–7.
15. Sarkar S, Strutz SE, Frank DM, Rivaldi C-L,
Sissel B, et al. (2010) Chagas disease risk in Texas.
PLOS Negl Trop Dis; 4: e836. doi: 10.1371/
journal.pntd.0000836.
16. Kjos SA, Snowden KF, Craig TM, Lewis B,
Ronald N, Olson JK (2008) Distribution and
characterization of canine Chagas disease in
Texas. Vet Parasitol 2008; 152: 249–56.
17. Cantey PT, Stramer SL, Townsend RL, Kamel
H, Ofafa K, et al. (2012) The United States
Trypanosoma cruzi infection study: evidence for
vector-borne transmission of the parasite that
causes Chagas disease among United States blood
donors. Transfusion; 52: 1922–30.
18. Stimpert KK, Montgomery SP (2010) Physician
awareness of Chagas disease, USA. Emerg Infect
Dis; 16: 871–2.
19. Centers for Disease Control and Prevention
(2012) Congenital transmission of Chagas disease
– Virginia, 2010. Morbidity and Mortality
Weekly Report (MMWR) July 6; 61: 477–9.
20. Yun O, Lima MA, Ellman T, ChambiW, Castillo
S, et al. (2009) Feasibility, drug safety, and
effectiveness of etiological treatment programs
for Chagas disease in Honduras, Guatemala, and
Bolivia: 10-year experience of Medicins Sans
Fronteires. PLOS Negl Trop Dis; 3: e488. doi:
10.1371/journal.pntd.0000488.
21. Bern C, Montgomery SP, Herwaldt BL, Rassi
A, Jr, Marin-Neto JA, et al (2007) Evaluation
and treatment of Chagas disease in the United
States: a systematic review. JAMA; 298: 2171–
81.
22. Viotti R, Vigliano C, Lococo B, Bertocchi G,
Petti M, et al. (2006) Long-term cardiac outcomes
of treating chronic Chagas disease with benzni-
dazole versus no treatment: a nonrandomized
trial. Ann Intern Med 2006; 144: 724–34.
23. Sanchez-Negrette O, Mora MC, Basombrio MA
(2005) High prevalence of congenital Trypanoso-
ma cruzi infection and family clustering in Salta,
Argentina. Pediatrics; 115: e668–72.
24. Minneman RM, Hennink MM, Nichols A, Salek
SS, Palomeque FS, et al (2012) Barriers to testing
and treatment for Chagas disease among Latino
immigrants in Georgia. J Parasitol Res. Epub
2012 Dec. 30.
25. Murcia L, Carrilero B, Munoz-Davila MJ,
Thomas MC, Lopez MC, Segovia M (2013) Risk
factors and primary prevention of congenital
Chagas disease in a nonendemic country. Clin
Infect Dis; 56: 496–502.
PLOS Neglected Tropical Diseases | www.plosntds.org 3 October 2013 | Volume 7 | Issue 10 | e2300
26. Sicuri E, Munoz J, Pinazo MJ, Posada E,
Sanchez J, et al. (2011). Economic evaluation
of Chagas disease screening of pregnant
Latin American women and of their infants
in a non endemic area. Acta Trop; 118:
110–7.
27. Martinez-Martinez E, Zaragoza ML, Solano E,
Figueroa B, Zuniga P, Laclette JP (2012)
Health research funding in Mexico: the need
for a long-term agenda. PLOS One; 7:
e51195. doi: 10.1371/journal.pone.0051195.
28. Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa
JA, Bezek S, et al. (2012) Chagas disease: ‘‘the
new HIV/AIDS of the Americas’’. PLOS Negl
Trop Dis 6: e1498. doi: 10.1371/journal.
pntd.0001498.
29. Dumonteil E, Bottazzi ME, Zhan B, Heffernan
MJ, Jones K, et al. (2012) Accelerating the
development of a therapeutic vaccine for human
Chagas disease: rationale and prospects. Expert
Rev Vaccines; 11: 1043–55.
PLOS Neglected Tropical Diseases | www.plosntds.org 4 October 2013 | Volume 7 | Issue 10 | e2300
